Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). ACME Laboratories's share price for the quarter that ended in Mar. 2026 was BDT75.5. ACME Laboratories's Shares Outstanding (EOP) for the quarter that ended in Mar. 2026 was 212 Mil. Therefore, ACME Laboratories's market cap for the quarter that ended in Mar. 2026 was BDT15,976 Mil.
ACME Laboratories's quarterly market cap
declined
from Sep. 2025 (BDT16,505 Mil) to Dec. 2025 (BDT15,003 Mil) but then
increased
from Dec. 2025 (BDT15,003 Mil) to Mar. 2026 (BDT15,976 Mil).
ACME Laboratories's annual market cap
declined
from Jun. 2022 (BDT18,811 Mil) to Jun. 2023 (BDT18,198 Mil) and
declined
from Jun. 2023 (BDT18,198 Mil) to Jun. 2024 (BDT14,495 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. ACME Laboratories's Enterprise Value for Today is BDT38,602 Mil.
ACME Laboratories (DHA:ACMELAB) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
ACME Laboratories Market Cap Related Terms
ACME Laboratories Market Cap Historical Data
* Premium members only.
The historical data trend for ACME Laboratories's Market Cap can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
DHA:ACMELAB vs ZTS, UTHR, VTRS: Market Cap Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, ACME Laboratories's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
ACME Laboratories Market Cap vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, ACME Laboratories's Market Cap distribution charts can be found below:
* The bar in red indicates where ACME Laboratories's Market Cap falls into.
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
ACME Laboratories's Market Cap for the fiscal year that ended in Jun. 2024 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ACME Laboratories (DHA:ACMELAB) has a Market Cap of BDT17,436 Mil as of Jul. 02, 2026. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on ACME Laboratories and its competitors. According to the industry distribution chart, ACME Laboratories ranks #568 out of 1023 companies in the Drug Manufacturers industry, placing it in the top 55.5%.
Is ACME Laboratories' Market Cap too high?
ACME Laboratories' current Market Cap is BDT17,436 Mil. Based on the distribution chart, ACME Laboratories ranks #568 out of 1023 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, ACME Laboratories has a GF Score™ of 82/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does ACME Laboratories' Market Cap compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, ACME Laboratories ranks #568 out of 1023 companies for Market Cap. This places ACME Laboratories in the lower half of its industry. The industry median Market Cap is 213.88. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Market Cap for a Drug Manufacturers company?
The median Market Cap among Drug Manufacturers companies is 213.88, based on 1,023 companies in the industry. Companies in the top quartile (top 25%) have a Market Cap significantly above this median, while those in the bottom quartile fall well below. However, Market Cap should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Market Cap mean?
A high Market Cap can signal that a stock is expensive relative to its fundamentals. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on ACME Laboratories and its competitors. For the Drug Manufacturers industry, the median Market Cap is 213.88 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. ACME Laboratories's current Market Cap is BDT17,436 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ACME Laboratories stock overvalued right now?
Based on GuruFocus' analysis, ACME Laboratories (DHA:ACMELAB) is currently considered Possible Value Trap. The stock's GF Value™ is BDT125.03, compared to a current price of BDT82.40 — trading 34.1% below its estimated fair value. The current Market Cap is BDT17,436 Mil. ACME Laboratories' overall GF Score™ is 82/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Market Cap calculated?
Market Cap is calculated from a company's financial statements. For ACME Laboratories (DHA:ACMELAB), the current Market Cap is BDT17,436 Mil as of Jul. 02, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is ACME Laboratories (DHA:ACMELAB) Overvalued in 2026?
Based on GuruFocus' analysis, ACME Laboratories stock appears to be undervalued.
The current stock price of BDT82.40 is trading 34.1% below its estimated GF Value™ of BDT125.03.
GuruFocus considers ACME Laboratories to be Possible Value Trap.
Key valuation signals for DHA:ACMELAB:
Market Cap: BDT17,436 Mil
GF Value™: BDT125.03 vs. price of BDT82.40 (34.1% below fair value)
No single metric tells the full story. See the DHA:ACMELAB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
ACME Laboratories Ltd is engaged in the manufacturing, marketing, and distribution of generic pharmaceutical products in Bangladesh. The Company is engaged in manufacturing, marketing, and distribution of generic pharmaceuticals formulation products which includes human drugs comprising dosages form like a tablet, capsule, dry syrup, cream, ointment, powder, injection, dry powder inhaler, metered dosage inhaler, suppository, eye and nasal drop, liquid, liquid in hard gelatine, Blow Fill Seal (BFS) products, sachet products; veterinary drugs comprising dosages form like bolus, liquid,injection, water-soluble powder, premix and herbal drugs comprising dosages form like liquid, capsule, tablet, cream. The products of the company are sold in domestic and international markets.
82GF Score
Get the complete analysis for DHA:ACMELAB
Market Cap is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
DHA:ACMELAB has been successfully added to your 
